CNBC · General

Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment

· By Elsa Ohlen
Story summary

Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker.

Read at CNBC

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.